Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:chemical_compound
|
| gptkbp:affects |
under investigation
|
| gptkbp:bioavailability |
moderate bioavailability
|
| gptkbp:chemical_formula |
C20 H24 N2 O2 S
|
| gptkbp:class |
gptkb:Bastiladon
|
| gptkbp:clinical_trial |
gptkb:United_States
Phase 2 measures of efficacy and safety sponsored by Allergan |
| gptkbp:collaborations |
with academic institutions
with pharmaceutical companies |
| gptkbp:collaborator |
various research institutions
|
| gptkbp:composed_by |
multi-step synthesis
|
| gptkbp:developed_by |
gptkb:Allergan
|
| gptkbp:discovery_year |
gptkb:2015
|
| gptkbp:dissolved |
soluble in DMSO
slightly soluble in water |
| gptkbp:dosage_form |
once daily
|
| gptkbp:drug_interactions |
potential interactions with other medications
|
| gptkbp:eligibility |
ongoing patient enrollment
|
| gptkbp:feedback |
generally positive
|
| gptkbp:funding |
funded by NIH
|
| https://www.w3.org/2000/01/rdf-schema#label |
ALX-0726
|
| gptkbp:invention |
US123456789
patented |
| gptkbp:investigates |
investigational new drug
|
| gptkbp:investment |
high potential in treatment market
|
| gptkbp:is_effective_against |
promising results in trials
|
| gptkbp:is_tested_for |
clinical trials
|
| gptkbp:knockouts |
high affinity for NTS1 receptor
|
| gptkbp:market_approval |
pending
|
| gptkbp:mechanism_of_action |
antagonist of neurotensin receptor
|
| gptkbp:patient_population |
adults with schizophrenia
|
| gptkbp:phase_completion |
completed Phase 1
ongoing Phase 2 |
| gptkbp:project |
in development
|
| gptkbp:publication |
published in medical journals
|
| gptkbp:regulatory_compliance |
not yet approved
|
| gptkbp:research |
conducted in animal models
|
| gptkbp:research_areas |
mental health
psychiatry |
| gptkbp:research_focus |
neuropsychiatric disorders
|
| gptkbp:research_output |
results published in peer-reviewed journals
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:safety_features |
under evaluation
|
| gptkbp:safety_measures |
ongoing safety monitoring
|
| gptkbp:scientific_goals |
improve treatment options for schizophrenia
|
| gptkbp:side_effect |
dizziness
fatigue nausea monitoring required |
| gptkbp:structure |
contains a sulfonamide group
|
| gptkbp:targets |
gptkb:neurotensin_receptor_1
schizophrenia |
| gptkbp:therapeutic_window |
narrow therapeutic window
|
| gptkbp:used_for |
treatment of schizophrenia
|
| gptkbp:weight |
348.48 g/mol
|
| gptkbp:bfsParent |
gptkb:Ablynx
|
| gptkbp:bfsLayer |
5
|